CO2019013768A2 - Compuestos de mic-1 y usos de estos - Google Patents

Compuestos de mic-1 y usos de estos

Info

Publication number
CO2019013768A2
CO2019013768A2 CONC2019/0013768A CO2019013768A CO2019013768A2 CO 2019013768 A2 CO2019013768 A2 CO 2019013768A2 CO 2019013768 A CO2019013768 A CO 2019013768A CO 2019013768 A2 CO2019013768 A2 CO 2019013768A2
Authority
CO
Colombia
Prior art keywords
compounds
mic
amino acid
polypeptide
extension
Prior art date
Application number
CONC2019/0013768A
Other languages
English (en)
Inventor
Henning Thøgersen
Xujia Zhang
Xiang Gao
Hongtao Guan
Kristian Sass-Ørum
Lars Fogh Iversen
Per Nørgaard
Sebastian Beck Jørgensen
Kristian Tage Hansen
Yi Wang
Kilian Waldemar Conde Frieboes
Birgit Wieczorek
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CO2019013768A2 publication Critical patent/CO2019013768A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a compuestos de MIC-1. Más específicamente se refiere a compuestos que comprenden un polipéptido MIC-1 con una extensión de aminoácidos en el N-terminal y un prolongador en donde la extensión de aminoácidos comprende de 3 a 36 residuos de aminoácidos y donde el polipéptido MIC-1 y la extensión de aminoácidos en el N-terminal juntos tienen un pI calculado menor que 6.5. Los compuestos de la invención tienen actividad de MIC-1. La invención se refiere, además, a composiciones farmacéuticas que comprenden tales compuestos y excipientes farmacéuticamente aceptables, así como también al uso médico de los compuestos.
CONC2019/0013768A 2017-05-23 2019-12-06 Compuestos de mic-1 y usos de estos CO2019013768A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017085576 2017-05-23
CN2017113335 2017-11-28
PCT/EP2018/063476 WO2018215525A1 (en) 2017-05-23 2018-05-23 Mic-1 compounds and uses thereof

Publications (1)

Publication Number Publication Date
CO2019013768A2 true CO2019013768A2 (es) 2020-04-01

Family

ID=62567604

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0013768A CO2019013768A2 (es) 2017-05-23 2019-12-06 Compuestos de mic-1 y usos de estos

Country Status (17)

Country Link
US (3) US20200079829A1 (es)
EP (1) EP3630805A1 (es)
JP (1) JP7015322B2 (es)
KR (1) KR20200010353A (es)
CN (1) CN111183148A (es)
AU (1) AU2018272911B2 (es)
BR (1) BR112019024102A2 (es)
CA (1) CA3064320A1 (es)
CL (1) CL2019003441A1 (es)
CO (1) CO2019013768A2 (es)
MA (1) MA48956A (es)
MX (1) MX2019013801A (es)
PE (1) PE20200514A1 (es)
PH (1) PH12019550241A1 (es)
RU (1) RU2019141031A (es)
TW (1) TWI710377B (es)
WO (1) WO2018215525A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2017202936A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
EP4041281A1 (en) 2019-10-04 2022-08-17 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN116925237A (zh) 2019-12-31 2023-10-24 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2005099746A1 (en) 2004-04-13 2005-10-27 St Vincent's Hospital Sydney Limited Method for modulating appetite
US20050256576A1 (en) 2004-05-13 2005-11-17 Moskowitz Nathan C Artificial expansile total lumbar and thoracic discs for posterior placement without supplemental instrumentation and its adaptation for anterior placement of artificial cervical, thoracic and lumbar discs
WO2005113606A2 (en) 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
AU2005266184A1 (en) 2004-07-26 2006-02-02 Asterion Limited Linkers
JP2010505437A (ja) 2006-10-13 2010-02-25 ノボ ノルディスク ヘルス ケア アーゲー 塩基性タンパク質タグに融合したプロセシング酵素
AU2008287340A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
BRPI1007313A2 (pt) * 2009-01-23 2016-02-10 Novo Nordisk As derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
WO2010091122A1 (en) * 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
EP2830646B1 (en) * 2012-03-27 2018-03-07 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
EP2950807B1 (en) 2013-01-30 2018-03-28 NGM Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
EA202092386A1 (ru) 2013-07-31 2021-04-30 Эмджен Инк. Конструкции на основе фактора дифференцировки и роста 15 (gdf15)
EP3705498A1 (en) 2013-08-22 2020-09-09 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
AU2015279525A1 (en) 2014-06-24 2016-12-15 Novo Nordisk A/S MIC-1 fusion proteins and uses thereof
WO2016102562A1 (en) 2014-12-23 2016-06-30 Novo Nordisk A/S Fgf21 derivatives and uses thereof
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
AU2016333538B2 (en) 2015-10-02 2022-03-31 Julius-Maximilians-Universität Würzburg GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
WO2017055613A2 (en) 2015-10-02 2017-04-06 Julius-Maximilians-Universität Würzburg Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
WO2017202936A1 (en) * 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and use thereof
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途

Also Published As

Publication number Publication date
TWI710377B (zh) 2020-11-21
CL2019003441A1 (es) 2020-05-08
MA48956A (fr) 2020-04-08
PH12019550241A1 (en) 2020-12-07
AU2018272911A1 (en) 2019-12-19
JP7015322B2 (ja) 2022-02-02
US10398782B2 (en) 2019-09-03
WO2018215525A8 (en) 2020-01-02
RU2019141031A (ru) 2021-06-16
EP3630805A1 (en) 2020-04-08
JP2020520918A (ja) 2020-07-16
US20200079829A1 (en) 2020-03-12
TW201900219A (zh) 2019-01-01
CN111183148A (zh) 2020-05-19
CA3064320A1 (en) 2018-11-29
WO2018215525A1 (en) 2018-11-29
US20180339057A1 (en) 2018-11-29
PE20200514A1 (es) 2020-03-05
RU2019141031A3 (es) 2021-07-16
KR20200010353A (ko) 2020-01-30
BR112019024102A2 (pt) 2020-06-02
US20230364248A1 (en) 2023-11-16
MX2019013801A (es) 2020-01-30
AU2018272911B2 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
CO2019013768A2 (es) Compuestos de mic-1 y usos de estos
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
AR100945A1 (es) Proteínas de fusión mic-1 y usos de las mismas
ECSP14016014A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardíaca
CL2019002132A1 (es) Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinético y sus usos.
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
SV2016005145A (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
GB2502716A (en) Fluorocarbon-linked peptide formulation
CL2017003144A1 (es) Péptidos lipidados resistentes a proteasas
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
BR112015007592A2 (pt) composições de enalapril
CO2019006652A2 (es) Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2017003201A1 (es) Variantes de il-37
WO2015086686A3 (en) Protease resistant peptides
ECSP22037660A (es) Agonistas del receptor npy2
WO2017211922A3 (en) Protease-resistant mono-lipidated peptides
MX2017011654A (es) Analogos ciclicos de galanina y usos de los mismos.
CL2019000099A1 (es) Factor vii de coagulación de larga duración y métodos para producir el mismo.
CL2017003143A1 (es) Composición multi-péptido.
MX2020009877A (es) Péptidos neutralizantes de miotoxina.
WO2018200814A3 (en) Modified cyclic peptides and therapeutic use thereof
MX2012007260A (es) Peptidos con actividad antibacteriana y antiparasitaria y diseño de los mismos.